Home > Oncology > ESMO 2021 > Genitourinary Cancer > HRR mutational status is prognostic and predictive biomarker olaparib activity

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By
Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA
Conference
ESMO 2021
Trial
Phase 3, NRG-GY004
Homologous recombination repair (HRR) mutation status in patients with recurrent, platinum-sensitive ovarian cancer is prognostic for progression-free survival (PFS) and predictive for activity of olaparib compared with chemotherapy, results from pre-planned exploratory analysis of the NRG-GY004 trial showed. Homologous recombination deficiency (HRD) is associated with improved efficacy of PARP inhibitors in patients with (recurrent) platinum-sensitive ovarian cancer, but interaction between HRD and combined anti-angiogenics and PARP inhibitors is unclear. Previously presented results from the randomised phase 3 NRG-GY004 trial (NCT02446600) did not show an improved PFS or overall response rate (ORR) of the combination cediranib/olaparib compared with platinum-based chemotherapy [1]. Assessment of outcomes by HRD status was a pre-planned translational endpoint. Re...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on